A Randomized Phase II Trial Comparing Bevacizumab Monotherapy With Dacarbazine (DTIC) in Treatment of Malignant Melanoma, Focusing on Angiogenic Markers and Prevention of Hypertension.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT01705392

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:36:16.805098+00:00

Published At

2017-02-24T00:00:00+00:00

Record Updated At

2017-02-24

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Metastatic Malignant Melanoma", "Unresectable Malignant Melanoma"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2017-02-24"

protocolSection.identificationModule.nctId

"NCT01705392"

protocolSection.identificationModule.officialTitle

"A Randomized Phase II Trial Comparing Bevacizumab Monotherapy With Dacarbazine (DTIC) in Treatment of Malignant Melanoma, Focusing on Angiogenic Markers and Prevention of Hypertension."

protocolSection.statusModule.overallStatus

"TERMINATED"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Metastatic Malignant Melanoma (protocolSection.conditionsModule.conditions)
• Unresectable Malignant Melanoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.